Frank J. Malinoski

TL;DR: The Wyeth Lederle as discussed by the authors determined the efficacy, safety and immunogenicity of the CRM197 pneumococcal conjugate vaccine against invasive disease caused by vaccine serotypes and to determine the effectiveness of this vaccine against clinical episodes of otitis media.

TL;DR: Primary immunization followed by a booster dose of PNCRM7 seemed to be acceptably safe and resulted in significant rises in antibody to all 7 serotypes, demonstrating effective stimulation of T-cell memory by the primary series of vaccinations.

TL;DR: The introduction and routine use of pneumococcal conjugate vaccine in the Northern California Kaiser Permanente population have been associated with a substantial reduction in invasive disease incidence in children <5 years of age, exceeding the average vaccine coverage substantially in each age group.

TL;DR: P pneumococcal oligosaccharide-CRM197 conjugate vaccine is able to induce an IgG serum response in infants and anti-pneumococcal antibody concentrations were significantly higher than in controls of same age.

TL;DR: Efficacy of the PFP-2 vaccine against lower respiratory tract illness during the RSV season was shown in RSV-seropositive children with cystic fibrosis and a significant enzyme-linked immunosorbent assay-fusion glycoprotein antibody response in nearly all the PF2 vaccinees.